Question 1

What is the difference between hemostasis and thrombosis?

Accepted Answer

Hemostasis is a vital process that stops bleeding from injured blood vessels through vasoconstriction, platelet adhesion, and fibrin formation. Thrombosis is the abnormal formation of blood clots within vessels that can obstruct blood flow and cause tissue damage. While hemostasis protects against excessive blood loss, thrombosis represents a pathological condition requiring treatment with anticoagulants.

Question 2

How do low-molecular-weight heparins work to prevent blood clotting?

Accepted Answer

Low-molecular-weight heparins are smaller fragments of unfractionated heparin that enhance antithrombin's ability to inhibit coagulation proteases. By binding to antithrombin, LMWHs prevent the enzyme cascade that leads to stable blood clot formation. This mechanism effectively stops pathological clotting while maintaining the body's natural hemostatic balance.

Question 3

Why are low-molecular-weight heparins preferred over unfractionated heparin?

Accepted Answer

Low-molecular-weight heparins offer superior pharmacokinetic properties compared to unfractionated heparin. LMWHs have greater bioavailability, longer half-lives, and more predictable effects, eliminating the need for close monitoring. Given subcutaneously with consistent dosing and fewer side effects, LMWHs are the preferred choice for anticoagulation therapy in most clinical settings.

Question 4

What are the main complications of thrombosis in different blood vessels?

Accepted Answer

Arterial thrombi, composed mainly of platelets within fibrin mesh, cause tissue ischemia and cell death, often associated with atherosclerosis. Venous thrombi develop a small white head and large red tail. Both types can break off as emboli and lodge in vital organs like the lungs or brain, causing severe complications including myocardial infarction and stroke.

Question 5

How does the endothelium regulate blood clotting?

Accepted Answer

The vascular endothelium plays a dual role in thrombosis regulation. It produces prostaglandin I2 and nitric oxide to inhibit platelet function and promote vasodilation. The endothelium also synthesizes tissue plasminogen activator and expresses thrombomodulin, which activates protein C—an anticoagulant that inactivates coagulation factors and prevents excessive clotting.

Question 6

What is the relationship between factor V Leiden and inherited thrombophilia?

Accepted Answer

Factor V Leiden is a genetic mutation that causes inherited thrombophilia by creating resistance to activated protein C. This mutation impairs the body's natural anticoagulant mechanisms, increasing susceptibility to abnormal blood clot formation. Individuals with this mutation have elevated risk for thrombotic and thromboembolic diseases requiring anticoagulant therapy.

Question 7

How do anticoagulants differ from antiplatelet drugs in treating thrombotic disease?

Accepted Answer

Injectable anticoagulants like low-molecular-weight heparins and oral anticoagulants target red thrombi by inhibiting coagulation cascades through antithrombin activation. Antiplatelet drugs, including prostaglandin synthesis inhibitors and glycoprotein IIb/IIIa inhibitors, treat platelet-rich white thrombi by preventing platelet aggregation. The choice depends on thrombus composition and clinical presentation.

항응고제: 저분자량 헤파린

Browse More Videos